tailieunhanh - Báo cáo khoa học: " The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: " The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. | Radiation Oncology BioMed Central Open Access Review The epidermal growth factor receptor EGFR in head and neck cancer its role and treatment implications Michel Zimmermann11 Abderrahim Zouhair11 David Azria2 and Mahmut Ozsahin 1 Address Department of Radiation Oncology Centre Hospitalier Universitaire Vaudois Bugnon 46 1011 Lausanne Switzerland and 2Department of Radiation Oncology INSERM Cancer Research Institute CRLC Val d Aurelle Rue Croix-Verte 34298 Montpellier cedex 05 France Email Michel Zimmermann - Abderrahim Zouhair - David Azria - azria@ Mahmut Ozsahin - Corresponding author fEqual contributors Published 02 May 2006 Received 26 January 2006 Radiation Oncology 2006 1 11 doi 1748-717X-1-11 Accepted 02 May 2006 This article is available from http content 1 1 1 1 2006 Zimmermann et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Epidermal growth factor receptor EGFR is a member of the ErbB family of receptors. Its stimulation by endogenous ligands EGF or transforming growth factor-alpha TGF-a results in activation of intracellular tyrosine kinase therefore cell cycle progression. High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers mostly in squamous-cell carcinoma of the head and neck SCCHN . Blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the receptor therefore in inhibition of cell proliferation enhanced apoptosis and reduced angiogenesis invasiveness and metastases. The EGFR is a prime target for new anticancer therapy in SCCHN and other agents in development include .

TÀI LIỆU LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.